BRPI1014802B8 - profármacos de triptolida. - Google Patents

profármacos de triptolida.

Info

Publication number
BRPI1014802B8
BRPI1014802B8 BRPI1014802A BRPI1014802A BRPI1014802B8 BR PI1014802 B8 BRPI1014802 B8 BR PI1014802B8 BR PI1014802 A BRPI1014802 A BR PI1014802A BR PI1014802 A BRPI1014802 A BR PI1014802A BR PI1014802 B8 BRPI1014802 B8 BR PI1014802B8
Authority
BR
Brazil
Prior art keywords
formula
compounds
triptolide prodrugs
triptolide
prodrugs
Prior art date
Application number
BRPI1014802A
Other languages
English (en)
Portuguese (pt)
Inventor
K Saluja Ashok
Gunda Georg Ingrid
Chugh Rohit
Prakash Patil Satish
M Vickers Selwyn
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of BRPI1014802A2 publication Critical patent/BRPI1014802A2/pt
Publication of BRPI1014802B1 publication Critical patent/BRPI1014802B1/pt
Publication of BRPI1014802B8 publication Critical patent/BRPI1014802B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI1014802A 2009-05-07 2010-05-07 profármacos de triptolida. BRPI1014802B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17624909P 2009-05-07 2009-05-07
US61/176,249 2009-05-07
PCT/US2010/034117 WO2010129918A1 (en) 2009-05-07 2010-05-07 Triptolide prodrugs

Publications (3)

Publication Number Publication Date
BRPI1014802A2 BRPI1014802A2 (pt) 2016-04-05
BRPI1014802B1 BRPI1014802B1 (pt) 2020-09-24
BRPI1014802B8 true BRPI1014802B8 (pt) 2021-05-25

Family

ID=42244313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014802A BRPI1014802B8 (pt) 2009-05-07 2010-05-07 profármacos de triptolida.

Country Status (17)

Country Link
US (1) US8507552B2 (OSRAM)
EP (1) EP2427467B1 (OSRAM)
JP (3) JP6000122B2 (OSRAM)
KR (1) KR101821823B1 (OSRAM)
CN (1) CN102596977B (OSRAM)
AU (1) AU2010245669B2 (OSRAM)
BR (1) BRPI1014802B8 (OSRAM)
CA (2) CA2964631A1 (OSRAM)
DK (1) DK2427467T3 (OSRAM)
EA (1) EA021135B1 (OSRAM)
ES (1) ES2552163T3 (OSRAM)
MX (1) MX2011011776A (OSRAM)
MY (1) MY160392A (OSRAM)
PL (1) PL2427467T3 (OSRAM)
PT (1) PT2427467E (OSRAM)
SG (1) SG175885A1 (OSRAM)
WO (1) WO2010129918A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
KR20150059746A (ko) 2012-08-23 2015-06-02 세네스텍 인코포레이티드 포유동물의 번식 능력을 감소시키는 방법
WO2014047783A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资(香港)有限公司 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
SG11201802915WA (en) * 2015-09-11 2018-05-30 Ys Ac Co Ltd Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体(上海)有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN110551171B (zh) * 2018-05-31 2021-07-27 欣凯医药化工中间体(上海)有限公司 一种雷公藤内酯醇衍生物的制备方法
WO2020056174A1 (en) 2018-09-13 2020-03-19 Minneamrita Therapeutics, LLC Triptolide and prodrugs thereof for use in methods to treat fibrosis, nash, and nafld
WO2021221179A1 (ja) * 2020-04-28 2021-11-04 国立大学法人高知大学 ヒト膵癌オルガノイドを用いたマウスモデルの樹立
JP2023538424A (ja) 2020-08-21 2023-09-07 ルヤン コーポレイション トリプトリドコンジュゲートおよびその使用
CN115227829B (zh) * 2022-02-22 2023-10-13 成都中医药大学 酸敏感性适配体雷公藤甲素偶联物及应用
WO2024186320A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of pancreatic cancer
WO2024187139A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
JP7759145B2 (ja) 2023-03-09 2025-10-23 ミネアムリタ セラピューティクス, エルエルシー 胃癌の治療のための薬物の組み合わせ

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
US5609991A (en) 1995-02-10 1997-03-11 Morton International, Inc. Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6548537B1 (en) 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
AU764123B2 (en) 1998-09-02 2003-08-07 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
AU3365800A (en) 1999-02-16 2000-09-04 Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells
AU5368699A (en) 1999-04-16 2000-11-02 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
EP1390358A4 (en) * 2001-03-15 2004-06-16 Pharmagenesis Inc AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNOMODULATORS AND ANTICROPHES
KR20100101011A (ko) * 2001-12-21 2010-09-15 에이자이 아이엔씨. 알콜 및 페놀의 수용성 포스포노옥시메틸 유도체를 제조하는 방법
CA2485794C (en) * 2002-05-31 2012-10-16 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
WO2004058246A1 (en) 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
CN1223595C (zh) 2002-12-27 2005-10-19 中国科学院上海药物研究所 雷公藤内酯醇衍生物及其应用
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005020887A2 (en) 2003-06-27 2005-03-10 Pharmagenesis, Inc. Method for treatment of severe acute respiratory syndrome
WO2005062913A2 (en) 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
JP5252765B2 (ja) 2003-12-26 2013-07-31 学校法人東京薬科大学 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤
AU2005218610B2 (en) 2004-03-02 2011-08-18 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
US20070244080A1 (en) 2004-06-25 2007-10-18 Pharmagenesis, Inc. Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
WO2007025031A2 (en) * 2005-08-24 2007-03-01 Cephalon, Inc. Prodrugs of indanone and tetralone compounds
CN101049300A (zh) 2006-04-04 2007-10-10 中国科学院上海药物研究所 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用
EP2079699A1 (en) 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
JP5221514B2 (ja) * 2007-03-06 2013-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物及びその製造方法
FI20070574A0 (fi) * 2007-07-30 2007-07-30 Kuopion Yliopisto Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke
WO2009023201A1 (en) 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Also Published As

Publication number Publication date
SG175885A1 (en) 2011-12-29
CN102596977A (zh) 2012-07-18
EP2427467A1 (en) 2012-03-14
KR101821823B1 (ko) 2018-01-24
HK1168107A1 (en) 2012-12-21
US8507552B2 (en) 2013-08-13
BRPI1014802B1 (pt) 2020-09-24
EP2427467B1 (en) 2015-08-05
DK2427467T3 (en) 2015-11-09
JP6000122B2 (ja) 2016-09-28
MX2011011776A (es) 2012-08-03
US20120238529A1 (en) 2012-09-20
CA2760953C (en) 2017-05-30
EA021135B1 (ru) 2015-04-30
WO2010129918A8 (en) 2011-01-20
PT2427467E (pt) 2015-11-19
CA2964631A1 (en) 2010-11-11
MY160392A (en) 2017-03-15
EA201190293A1 (ru) 2012-11-30
KR20120015339A (ko) 2012-02-21
AU2010245669A1 (en) 2011-12-01
BRPI1014802A2 (pt) 2016-04-05
WO2010129918A1 (en) 2010-11-11
CA2760953A1 (en) 2010-11-11
JP2014185181A (ja) 2014-10-02
JP2012526148A (ja) 2012-10-25
ES2552163T3 (es) 2015-11-26
PL2427467T3 (pl) 2016-04-29
CN102596977B (zh) 2016-06-29
AU2010245669B2 (en) 2015-11-26
JP2016065099A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
BRPI1014802B8 (pt) profármacos de triptolida.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112014030743A2 (pt) inibidores de neprilisina
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BR112012008073A2 (pt) compostos heterocíclicos como inibidores de janus quinase
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
BRPI1009637A2 (pt) composto, composição e uso de um composto
BR112012008147A2 (pt) compostos heteroarílicos como inibidores da quinase
PH12014500987A1 (en) Neprilysin inhibitors
BR112014013661A2 (pt) Derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112013016595A2 (pt) inibidores de neprilisina
ECSP12012290A (es) Formulaciones farmacéuticas
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
MY172924A (en) Neprilysin inhibitors
CR20140134A (es) Composiciones farmacéuticas
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF